Vaxart Reports Has Formed Manufacturing, Quality Advisory Board
Vaxart, Inc. (NASDAQ:VXRT), today announced that it has formed a Manufacturing and Quality Advisory Board.   "We are very excited to be able to tap into the vast knowledge of this group of experts," said
Benzinga · 23h ago
VaxartAnnounces Creation ofManufacturing and QualityAdvisory Board
/PRNewswire/ -- Vaxart, Inc. (NASDAQ: VXRT),today announcedthat it hasformed a Manufacturing and QualityAdvisoryBoard.
PR Newswire - PRF · 23h ago
Vaxart Announces Creation of Manufacturing and Quality Advisory Board
Vaxart, Inc. (NASDAQ: VXRT), today announced that it has formed a Manufacturing and Quality Advisory Board.
PR Newswire · 23h ago
Vaxartto Present at the 2021 Cantor Virtual Global Healthcare Conference on Thursday, September 30
/PRNewswire/ -- Vaxart, Inc. (NASDAQ: VXRT) today announced that Chief Executive Officer Andrei Floroiu and Chief Scientific Officer Dr. present at the 2021 Cantor Virtual Global Healthcare Conference at , September 30, 2021. 
PR Newswire - PRF · 2d ago
BRIEF-Vaxart May Offer And Sell Shares With Aggregate Offering Price Of Up To $100 Mln · 6d ago
Vaxart Looks To Be On The Verge Of Breaking Out Of A Pattern
Vaxart Inc. (NASDAQ: VXRT) shares are trading lower Monday, possibly after retail traders were able to push the stock higher. The stock looks to be almost breaking out of a technical pattern. Vaxart was down 4.74% at $8.35 at last check Monday afternoon.
Benzinga · 09/13 19:45
Vaxart Stock Is One Vaccine Also-Ran Worth Another Look
Investor Place · 09/08 10:00
Vaxartto Present at the H.C. Wainwright 23rd Annual Global Investment Conference
/PRNewswire/ -- Vaxart, Inc. (Nasdaq: VXRT) today announced that , President and CEO, and Dr. , SVP and Chief Scientific Officer, will present at the H.C. Wainwright 23 Annual Global Investor Conference taking place .
PR Newswire - PRF · 09/07 20:20
Vaxart, Inc.'s (NASDAQ:VXRT) Shift From Loss To Profit
Vaxart, Inc. ( NASDAQ:VXRT ) is possibly approaching a major achievement in its business, so we would like to shine...
Simply Wall St. · 08/23 18:45
BRIEF-Vaxart Announces Julie M. Cherrington Joins Board Of Directors · 08/23 13:11
Vaxart Announces Highly Regarded Biotech Executive Julie M. Cherrington, Ph.D., Joins Board of Directors
/PRNewswire/ -- Vaxart, Inc. (NASDAQ: VXRT) today announced the addition of , Ph.D., to the company's board of directors. Dr. Cherrington is an experienced life science executive with extensive insights into taking drugs through the development process to ...
PR Newswire - PRF · 08/23 13:01
BRIEF-Vaxart Announces Creation Of New Scientific And Clinical Advisory Board · 08/19 21:43
Private Portfolio Partners LLC Buys O`Shares Global Internet Giants ETF, iShares 10-20 Year ...
GuruFocus News · 08/13 19:38
Insider Trends: 90-Days of Insider Buying at Vaxart Interrupted with Share Disposition
MT Newswires · 08/11 19:06
7 Biotech Stocks to Buy Amid the Delta Variant’s Onslaught
Investor Place · 08/11 16:57
Is the Options Market Predicting a Spike in Vaxart (VXRT) Stock? · 08/11 12:54
The Delta Variant Is a Shot in the Arm for Vaxart’s Pill Vaccine
Investor Place · 08/10 20:13
Unusual Options Activity Insight: Vaxart
Shares of Vaxart (NASDAQ:VXRT) saw some unusual options activity on Tuesday. Following the unusual option alert, the stock price moved up to $10.11.
Benzinga · 08/10 14:50
VAXART, INC. (VXRT) Reports Q2 Loss, Misses Revenue Estimates
VAXART, INC. (VXRT) delivered earnings and revenue surprises of 7.14% and -79.64%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 08/05 22:35
Webull provides a variety of real-time VXRT stock news. You can receive the latest news about VAXART through multiple platforms. This information may help you make smarter investment decisions.
About VXRT
Vaxart, Inc. is a clinical-stage biotechnology company. The Company is focused on developing oral recombinant vaccines based on its vector-adjuvant-antigen standardized technology (VAAST) proprietary oral vaccine platform. Its oral vaccines are designed to generate immune responses that protect against a range of infectious diseases and will be useful for the treatment of chronic viral infections and cancer. It is developing prophylactic vaccine candidates that target a range of infectious diseases, including SARS-CoV-2, the virus that causes coronavirus disease 2019 (COVID-19), norovirus, seasonal influenza and respiratory syncytial virus (RSV). The Company is also developing therapeutic vaccine targeting cervical cancer and dysplasia caused by human papillomavirus (HPV).